Russell Frank Company’s Akebia Therapeutics AKBA Stock Holding History

Russell Frank Company’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-111,169	Closed	-$1.41M	–	2960
2015 Q4	$1.41M	Buy	111,169 +56,251	+102%	+$574K	﹤0.01%	2041
2015 Q3	$531K	Buy	+54,918	New	+$504K	﹤0.01%	2455

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's AKBA Position: Q1 2016 in Review

Russell Frank Company sold out of Akebia Therapeutics (AKBA) in Q1 2016, closing a stake of 111,169 shares — an estimated $1.41M sold.

Russell Frank Company first reported a position in AKBA in Q3 2015 and held it in 2 quarters. The position peaked at $1.41M in Q4 2015. 91 funds tracked by Wall St. Rank hold AKBA as of Q1 2016.

Russell Frank Company reported no remaining Akebia Therapeutics position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 111,169 Akebia Therapeutics shares in Q1 2016, an estimated $1.41M.
Russell Frank Company first reported a position in Akebia Therapeutics in Q3 2015 and held it in 2 quarters.
Russell Frank Company's Akebia Therapeutics position peaked at $1.41M in Q4 2015.
91 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.